Innate Pharma Secures Sobi Deal to Extend Cash Runway

Innate Pharma (NASDAQ: IPHA) has secured a strategic partnership with Sobi that includes a $75 million upfront payment for the development and commercialization of lacutamab. This deal, combined with a €30 million equity financing, extends the company's projected cash runway through the end of the first quarter of 2028. The agreement grants Sobi exclusive global commercialization rights if the drug achieves accelerated approval, while Innate retains control over the ongoing clinical trials.

The company has initiated the TELLOMAK-3 phase III trial, with the first patient enrollment scheduled for the first quarter of 2027. Innate plans to file for accelerated approval for Sézary syndrome in the second half of 2027 based on existing phase II data. This regulatory strategy aims to bring the anti-KIR3DL2 antibody to market sooner while the confirmatory trial progresses, leveraging FDA Breakthrough Therapy and Fast Track designations.

Sobi Agreement Defines Financial Structure

According to details reported by GN markets/earnings (en-US), the Sobi deal provides immediate liquidity to support Innate's clinical obligations. The upfront $75 million payment is followed by up to $40 million in near-term milestones specific to Sézary syndrome. Additionally, the contract includes up to $465 million tied to development-rights options and future regulatory and commercial milestones, alongside tiered double-digit royalties on net sales.

CEO Jonathan Dickinson stated that the transaction became effective upon closing, allowing Innate to fund the TELLOMAK-3 trial without further immediate dilution. The company expects physicians to use the treatment off-label in earlier lines of therapy once NCCN guidelines include the drug, potentially expanding the addressable market beyond the initial Sézary syndrome indication.

Lacutamab Regulatory Pathway Accelerates

Lacutamab holds FDA Breakthrough Therapy designation for relapsed or refractory Sézary syndrome, as well as FDA Fast Track, EMA PRIME, and orphan-drug designations in the U.S. and Europe. Chief Medical Officer Markus Jensen confirmed that Innate will conduct the phase III trial and file for accelerated approval. If approved, Sobi assumes exclusive global commercialization rights, shifting the financial burden of marketing and distribution away from Innate.

Pricing research conducted with U.S. payers suggests an annual cost per patient between €500,000 and €625,000. This price point is supported by clinical data and the potential listing in National Comprehensive Cancer Network guidelines. The company anticipates that this pricing model will be viable given the severity of the disease and the lack of effective alternatives for this patient population.

PACIFIC-9 and IPH4502 Progress

Innate expects key clinical updates in the second half of 2026, including the PACIFIC-9 phase III readout for monalizumab. The company has completed enrollment for this study, which targets a different lymphoma subtype. Additionally, initial phase I data for IPH4502, an antibody-drug conjugate, is forthcoming. IPH4502 has shown preliminary responses in heavily pretreated solid-tumor populations, with dose-escalation and cohort-enrichment enrollment now complete.

These developments provide Innate with a diversified pipeline of late-stage assets. The combination of secured funding, regulatory milestones for lacutamab, and pending data for monalizumab and IPH4502 positions the company to generate value from multiple fronts. The cash runway extension through early 2028 provides sufficient time to navigate these regulatory and clinical checkpoints without urgent capital market activity.